Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonavalent human papillomavirus vaccine immunogenicity in female adolescents aged 9 to under 15 years
TCTR20250703004Phase 2Active, not recruiting
- Sponsor
- Faculty of Medicine, Chulalongkorn University
- Start
- Oct 2025
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, Cervical Cancer (CC), anogenital warts and 4 more, sponsored by Faculty of Medicine, Chulalongkorn University. Primary endpoint: Primary immunogenicity endpoint. Started Oct 2025; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)anogenital wartsanal cancervaginal cancer
Beyond the preview
Go deeper on TCTR20250703004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250703004.